{ "schemaVersion": 1, "organisationId": "O-c152559419cd47e2aaf60f66cf94e314", "slug": "biomerieux", "name": "BIOMERIEUX", "updatedAt": "2026-10-04T15:07:13.34814Z", "sections": [ { "type": "OVERVIEW", "text": "bioMérieux is a French in-vitro diagnostics company whose core business is developing diagnostic systems, reagents, software and services. Its solutions identify infectious diseases and microorganisms in food, pharmaceutical and cosmetic products, across clinical diagnostics, microbiology, molecular biology, immunoassays and industrial applications [P112464929][T12455926]. The company says its purpose is to help make the world healthier, and it reports operations in 45 countries with products distributed in more than 160 countries [https://www.biomerieux.com/corp/en/who-we-are/our-company-purpose.html][https://www.biomerieux.com/us/en/who-we-are/biomerieux-worldwide.html].\n\nFounded in 1963, bioMérieux reported 2025 consolidated sales of €4.070 billion. Its Q1 2026 sales were €984 million. The company’s website reports 14,600 team members, without specifying a reporting date [P18434865][P83099480][https://www.biomerieux.com/corp/en/our-responsibility/team-members.html][https://www.biomerieux.com/corp/en/who-we-are/our-legacy.html].\n[P112464929][T12455926][P18434865][P83099480][https://www.biomerieux.com/corp/en/who-we-are/our-company-purpose.html][https://www.biomerieux.com/us/en/who-we-are/biomerieux-worldwide.html][https://www.biomerieux.com/corp/en/our-responsibility/team-members.html][https://www.biomerieux.com/corp/en/who-we-are/our-legacy.html]", "updatedAt": "2026-10-04T15:07:13.34814Z" }, { "type": "PRODUCTS", "text": "bioMérieux’s clinical diagnostics portfolio includes BIOFIRE®/FILMARRAY® multiplex PCR panels for syndromic infectious-disease testing, with testing generally taking about 15 minutes to an hour [https://www.biomerieux.com/corp/en/our-offer/point-of-care/product-range/biofire-syndromic-approach-pcr-testing-and-diagnostics.html]. The BIOFIRE® SPOTFIRE® modular system is designed for point-of-care multiplex PCR, with respiratory and sore-throat panel results described as available in about 15 minutes [https://www.biomerieux.com/corp/en/our-offer/clinical-products/biofire-spotfire-system.html][https://www.biomerieux.com/us/en/our-offer/clinical-products/biofire-spotfire-rst.html]. Other laboratory systems include VITEK® 2 for automated microbial identification and antimicrobial susceptibility testing, VITEK® MS PRIME for MALDI-TOF microbial identification, BACT/ALERT® VIRTUO® for automated blood-culture microbial detection, and VIDAS® 3, an automated on-demand immunoassay system using ELFA technology [https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-2.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-ms-prime.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/bact-alert-virtuo.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/vidas-3.html].\n\nFor food and industrial quality testing, TEMPO® automates enumeration of quality indicators, GENE-UP® is a real-time PCR platform for detecting pathogens, viruses and spoilage, and CHEMUNEX® D-COUNT® provides rapid detection and enumeration of spoilage microorganisms [https://www.biomerieux.com/corp/en/our-offer/industry-products/tempo-automated-quality-indicator.html][https://www.biomerieux.com/corp/en/our-offer/industry-products/gene-up-automated-pathogen-detection.html][https://www.biomerieux.com/corp/en/our-offer/industry-products/chemunex-d-count-rapid-microbial-testing.html]. Related services include customer support, analytics and consultancy, remote or on-site assistance, and preventive maintenance [https://www.biomerieux.com/us/en/service-and-support/service/total-service-solutions.html].\n\nIn FY2025, reported sales were €4,069.8 million: Clinical Applications accounted for €3,430.8 million (about 84.3%) and Industrial Applications €638.9 million (about 15.7%). Clinical Applications included €1,733.0 million in molecular biology (about 42.6% of total sales), €1,339.0 million in microbiology (32.9%), and €308.3 million in immunoassays (7.6%). BIOFIRE sales were €1,512.1 million (about 37.2% of total), and SPOTFIRE sales were €167.5 million (about 4.1%); these are application and product-line sales figures, respectively [T148498][T12455926].\n[T148498][T12455926][https://www.biomerieux.com/corp/en/our-offer/point-of-care/product-range/biofire-syndromic-approach-pcr-testing-and-diagnostics.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/biofire-spotfire-system.html][https://www.biomerieux.com/us/en/our-offer/clinical-products/biofire-spotfire-rst.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-2.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-ms-prime.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/bact-alert-virtuo.html][https://www.biomerieux.com/corp/en/our-offer/clinical-products/vidas-3.html][https://www.biomerieux.com/corp/en/our-offer/industry-products/tempo-automated-quality-indicator.html][https://www.biomerieux.com/corp/en/our-offer/industry-products/gene-up-automated-pathogen-detection.html][https://www.biomerieux.com/corp/en/our-offer/industry-products/chemunex-d-count-rapid-microbial-testing.html][https://www.biomerieux.com/us/en/service-and-support/service/total-service-solutions.html]", "updatedAt": "2026-10-04T15:07:13.34814Z" }, { "type": "GEOGRAPHY", "text": "In FY 2025, bioMérieux generated sales across four reported regions: North America (45%), EMEA (32%), Asia Pacific (16%) and Latin America (7%). [P2253984] The company reported a presence in 46 countries and distribution reach to more than 160 countries; over 94% of revenue was generated outside France. [P112199035] Its FY 2025 results reported 15,000 team members, but the cited disclosures do not provide a regional employee breakdown. [https://www.biomerieux.com/corp/en/journalists/press-releases/2025-financial-results.html]\n\nThe company’s registered office is in Marcy-l’Étoile, France. [https://www.biomerieux.com/content/dam/biomerieux-com/investor/gouvernance/statuts/2025/VDEF-Projet_Statuts_bMxSA---AG-2025.pdf] Company materials describe 15 manufacturing sites worldwide. [https://www.biomerieux.com/corp/en/candidates/job-profiles/manufacturing-logistics-supply-chain.html] La Balme-les-Grottes is a French production and development location; in 2026, bioMérieux announced a planned facility there to manufacture BIOFIRE PCR tests for the European market. [https://www.biomerieux.com/fr/fr/qui-nous-sommes/actualites-societe/la-balme-site-inauguration-labnext-plasteam.html][https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-invests-in-france-with-a-new-facility-to-produce-innovative-diagnostics.html]\n[P2253984][P112199035][https://www.biomerieux.com/corp/en/journalists/press-releases/2025-financial-results.html][https://www.biomerieux.com/content/dam/biomerieux-com/investor/gouvernance/statuts/2025/VDEF-Projet_Statuts_bMxSA---AG-2025.pdf][https://www.biomerieux.com/corp/en/candidates/job-profiles/manufacturing-logistics-supply-chain.html][https://www.biomerieux.com/fr/fr/qui-nous-sommes/actualites-societe/la-balme-site-inauguration-labnext-plasteam.html][https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-invests-in-france-with-a-new-facility-to-produce-innovative-diagnostics.html]", "updatedAt": "2026-10-04T15:07:13.34814Z" }, { "type": "SEGMENTS", "text": "For FY2025, bioMérieux reported sales across two application categories: Clinical Applications (€3,430.8 million; approximately 84.3% of total sales) and Industrial Applications (€638.9 million; approximately 15.7%). These percentages are calculated from reported total sales of €4,069.8 million. [T148498] Clinical Applications cover diagnostic offerings for clinical laboratories; Industrial Applications serve industrial microbiology, including food safety and quality and pharmaceutical quality control. [https://www.biomerieux.com/us/en/our-offer/in-hospital-in-lab/clinical-laboratories.html][https://www.biomerieux.com/corp/en/our-offer/industrial-microbiology-applications.html][https://www.biomerieux.com/corp/en/our-offer/food-safety-and-quality.html][https://www.biomerieux.com/us/en/our-offer/pharmaceutical-quality-control.html]\n\nWithin Clinical Applications, FY2025 sales were Molecular Biology (€1,733.0 million; approximately 42.6% of total sales), Microbiology (€1,339.0 million; 32.9%), Immunoassays (€308.3 million; 7.6%) and Other Lines (€50.6 million; 1.2%). These are application-level sales categories; the cited FY2025 sales breakdown does not present separate operating results for them. [T148498][https://www.biomerieux.com/corp/en/journalists/press-releases/2025-financial-results.html]\n[T148498][T148498][T148498][T148498][T148498][T148498][T148498][https://www.biomerieux.com/us/en/our-offer/in-hospital/in-lab/clinical-laboratories.html][https://www.biomerieux.com/corp/en/our-offer/industrial-microbiology-applications.html][https://www.biomerieux.com/corp/en/our-offer/food-safety-and-quality.html][https://www.biomerieux.com/us/en/our-offer/pharmaceutical-quality-control.html][https://www.biomerieux.com/corp/en/journalists/press-releases/2025-financial-results.html]", "updatedAt": "2026-10-04T15:07:13.34814Z" }, { "type": "HISTORY", "text": "Alain Mérieux founded B-D Mérieux in 1963 in Marcy-l’Étoile, France, as a joint venture with Becton-Dickinson; it became bioMérieux SA in 1968 after Mérieux acquired Institut Mérieux’s stake, and Alain Mérieux held a majority stake by 1974. The company began expanding internationally in the 1970s, including establishing a presence in Brazil in 1973. [https://www.biomerieux.com/corp/en/who-we-are/our-legacy.html] [T8590433]\n\nFrom the 1980s onward, acquisitions broadened its diagnostic portfolio, including API in 1986, VITEK in 1988 and Organon Teknika, associated with BACT/ALERT, in 2001. bioMérieux went public in Paris in 2004 and acquired BioFire Diagnostics in 2014, adding its BIOFIRE FILMARRAY molecular diagnostics range. Later acquisitions included Astute Medical and a majority stake in Hybiome in 2018, Invisible Sentinel in 2019, Specific Diagnostics in 2022 and Lumed in 2024. [T8590433] [https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-finalizes-acquisition-us-company-biofire-specialized-molecular-biology.html]\n\nIn a planned leadership succession, Jean-Luc Bélingard was appointed president in 2009. Alexandre Mérieux became Chairman and CEO in 2017; in 2023 he became Executive Chairman, with Pierre Boulud appointed CEO. [https://www.biomerieux.com/corp/en/journalists/press-releases/alain-merieux-organizes-his-succession-head-biomerieux-entrusting-jean-luc-belingard-role-president.html] [https://www.biomerieux.com/corp/en/journalists/press-releases/alexandre-merieux-appointed-chairman-and-ceo-biomerieux.html] [https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-evolves-its-governance--alexandre-merieux-becomes-exe.html]\n[T8590433][https://www.biomerieux.com/corp/en/who-we-are/our-legacy.html][https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-finalizes-acquisition-us-company-biofire-specialized-molecular-biology.html][https://www.biomerieux.com/corp/en/journalists/press-releases/alain-merieux-organizes-his-succession-head-biomerieux-entrusting-jean-luc-belingard-role-president.html][https://www.biomerieux.com/corp/en/journalists/press-releases/alexandre-merieux-appointed-chairman-and-ceo-biomerieux.html][https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-evolves-its-governance--alexandre-merieux-becomes-exe.html]", "updatedAt": "2026-10-04T15:07:13.34814Z" } ], "sources": [ { "id": "P112464929", "href": "https://app.finbar.com/go?id=P112464929", "label": "BIOMERIEUX — Press release (2025 Y), p8", "documentId": "D-74258f78d47c491985b3755c9f466580", "page": 8 }, { "id": "T12455926", "href": "https://app.finbar.com/go?id=T12455926", "label": "BIOMERIEUX — Press release (2025 Y), p9", "documentId": "D-74258f78d47c491985b3755c9f466580", "page": 9 }, { "id": "https://www.biomerieux.com/corp/en/who-we-are/our-company-purpose.html", "href": "https://www.biomerieux.com/corp/en/who-we-are/our-company-purpose.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/us/en/who-we-are/biomerieux-worldwide.html", "href": "https://www.biomerieux.com/us/en/who-we-are/biomerieux-worldwide.html", "label": "www.biomerieux.com" }, { "id": "P18434865", "href": "https://app.finbar.com/go?id=P18434865", "label": "BIOMERIEUX — Press release (2025 Y), p2", "documentId": "D-74258f78d47c491985b3755c9f466580", "page": 2 }, { "id": "P83099480", "href": "https://app.finbar.com/go?id=P83099480", "label": "BIOMERIEUX — Press release (2026 Q 1), p2", "documentId": "D-450d90d93c874c21a7ae73bc581f5517", "page": 2 }, { "id": "https://www.biomerieux.com/corp/en/our-responsibility/team-members.html", "href": "https://www.biomerieux.com/corp/en/our-responsibility/team-members.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/who-we-are/our-legacy.html", "href": "https://www.biomerieux.com/corp/en/who-we-are/our-legacy.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/point-of-care/product-range/biofire-syndromic-approach-pcr-testing-and-diagnostics.html", "href": "https://www.biomerieux.com/corp/en/our-offer/point-of-care/product-range/biofire-syndromic-approach-pcr-testing-and-diagnostics.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/biofire-spotfire-system.html", "href": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/biofire-spotfire-system.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/us/en/our-offer/clinical-products/biofire-spotfire-rst.html", "href": "https://www.biomerieux.com/us/en/our-offer/clinical-products/biofire-spotfire-rst.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-2.html", "href": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-2.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-ms-prime.html", "href": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-ms-prime.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/bact-alert-virtuo.html", "href": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/bact-alert-virtuo.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/vidas-3.html", "href": "https://www.biomerieux.com/corp/en/our-offer/clinical-products/vidas-3.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/industry-products/tempo-automated-quality-indicator.html", "href": "https://www.biomerieux.com/corp/en/our-offer/industry-products/tempo-automated-quality-indicator.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/industry-products/gene-up-automated-pathogen-detection.html", "href": "https://www.biomerieux.com/corp/en/our-offer/industry-products/gene-up-automated-pathogen-detection.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/industry-products/chemunex-d-count-rapid-microbial-testing.html", "href": "https://www.biomerieux.com/corp/en/our-offer/industry-products/chemunex-d-count-rapid-microbial-testing.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/us/en/service-and-support/service/total-service-solutions.html", "href": "https://www.biomerieux.com/us/en/service-and-support/service/total-service-solutions.html", "label": "www.biomerieux.com" }, { "id": "T148498", "href": "https://app.finbar.com/go?id=T148498", "label": "BIOMERIEUX — Press release (2025 Y), p3", "documentId": "D-74258f78d47c491985b3755c9f466580", "page": 3 }, { "id": "P2253984", "href": "https://app.finbar.com/go?id=P2253984", "label": "BIOMERIEUX — Presentation (2025 Y), p12", "documentId": "D-5b8bdf268f804c21bdb3e30fcfddb9ae", "page": 12 }, { "id": "P112199035", "href": "https://app.finbar.com/go?id=P112199035", "label": "BIOMERIEUX — Press release (2025 Y), p8", "documentId": "D-74258f78d47c491985b3755c9f466580", "page": 8 }, { "id": "https://www.biomerieux.com/corp/en/journalists/press-releases/2025-financial-results.html", "href": "https://www.biomerieux.com/corp/en/journalists/press-releases/2025-financial-results.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/content/dam/biomerieux-com/investor/gouvernance/statuts/2025/VDEF-Projet_Statuts_bMxSA---AG-2025.pdf", "href": "https://www.biomerieux.com/content/dam/biomerieux-com/investor/gouvernance/statuts/2025/VDEF-Projet_Statuts_bMxSA---AG-2025.pdf", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/candidates/job-profiles/manufacturing-logistics-supply-chain.html", "href": "https://www.biomerieux.com/corp/en/candidates/job-profiles/manufacturing-logistics-supply-chain.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/fr/fr/qui-nous-sommes/actualites-societe/la-balme-site-inauguration-labnext-plasteam.html", "href": "https://www.biomerieux.com/fr/fr/qui-nous-sommes/actualites-societe/la-balme-site-inauguration-labnext-plasteam.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-invests-in-france-with-a-new-facility-to-produce-innovative-diagnostics.html", "href": "https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-invests-in-france-with-a-new-facility-to-produce-innovative-diagnostics.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/us/en/our-offer/in-hospital-in-lab/clinical-laboratories.html", "href": "https://www.biomerieux.com/us/en/our-offer/in-hospital-in-lab/clinical-laboratories.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/industrial-microbiology-applications.html", "href": "https://www.biomerieux.com/corp/en/our-offer/industrial-microbiology-applications.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/our-offer/food-safety-and-quality.html", "href": "https://www.biomerieux.com/corp/en/our-offer/food-safety-and-quality.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/us/en/our-offer/pharmaceutical-quality-control.html", "href": "https://www.biomerieux.com/us/en/our-offer/pharmaceutical-quality-control.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/us/en/our-offer/in-hospital/in-lab/clinical-laboratories.html", "href": "https://www.biomerieux.com/us/en/our-offer/in-hospital/in-lab/clinical-laboratories.html", "label": "www.biomerieux.com" }, { "id": "T8590433", "href": "https://app.finbar.com/go?id=T8590433", "label": "BIOMERIEUX — Full financial report (2024 Y), p21", "documentId": "D-a727c98ad6fb439881cbfea7a159eb2f", "page": 21 }, { "id": "https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-finalizes-acquisition-us-company-biofire-specialized-molecular-biology.html", "href": "https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-finalizes-acquisition-us-company-biofire-specialized-molecular-biology.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/journalists/press-releases/alain-merieux-organizes-his-succession-head-biomerieux-entrusting-jean-luc-belingard-role-president.html", "href": "https://www.biomerieux.com/corp/en/journalists/press-releases/alain-merieux-organizes-his-succession-head-biomerieux-entrusting-jean-luc-belingard-role-president.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/journalists/press-releases/alexandre-merieux-appointed-chairman-and-ceo-biomerieux.html", "href": "https://www.biomerieux.com/corp/en/journalists/press-releases/alexandre-merieux-appointed-chairman-and-ceo-biomerieux.html", "label": "www.biomerieux.com" }, { "id": "https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-evolves-its-governance--alexandre-merieux-becomes-exe.html", "href": "https://www.biomerieux.com/corp/en/journalists/press-releases/biomerieux-evolves-its-governance--alexandre-merieux-becomes-exe.html", "label": "www.biomerieux.com" } ] }